Personal information

Other IDs

SciProfiles: 3711134

Biography

Clinical research physician (subinvestigator) at the Center for Vaccinology, Ghent University Hospital

Activities

Collapse all

Employment (1)

Ghent University Hospital: Ghent, Flanders, BE

2020-07-01 to present | Sub-investigator (Center for Vaccinology Ghent)
Employment
Source: Self-asserted source
Bart Jacobs

Education and qualifications (1)

Ghent University: Ghent, Flanders, BE

2007-06-30 to present | MD (Health department)
Education
Source: Self-asserted source
Bart Jacobs

Works (8)

Evaluation of Safety, Immunogenicity and Cross-Reactive Immunity of OVX836, a Nucleoprotein-Based Universal Influenza Vaccine, in Older Adults

Vaccines
2024-12-11 | Journal article
DOI: 10.3390/vaccines12121391
Contributors: Bart Jacobs; Isabel Leroux-Roels; Jacques Bruhwyler; Nicola Groth; Gwenn Waerlop; Yorick Janssens; Jessika Tourneur; Fien De Boever; Azhar Alhatemi; Philippe Moris et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Safety and Immunogenicity of an Adjuvanted <i>Clostridioides difficile</i> Vaccine Candidate in Healthy Adults: A Randomized Placebo-Controlled Phase 1 Study

The Journal of Infectious Diseases
2024-10-24 | Journal article
DOI: 10.1093/infdis/jiae466
Part of ISSN: 0022-1899
Part of ISSN: 1537-6613
Contributors: Isabel Leroux-Roels; Azhar Alhatemi; Magalie Caubet; Fien De Boever; Bertrand de Wergifosse; Mohamed El Idrissi; Guilherme S Ferreira; Bart Jacobs; Axel Lambert; Sandra Morel et al.
Source: Self-asserted source
Bart Jacobs

Safety and Immunogenicity of a Carbohydrate Fatty Acid Monosulphate Ester Adjuvant Combined with a Low-Dose Quadrivalent Split-Virion Inactivated Influenza Vaccine: A Randomised, Observer-Blind, Active-Controlled, First-in-Human, Phase 1 Study

Vaccines
2024-09-10 | Journal article
DOI: 10.3390/vaccines12091036
Contributors: Valentino D’Onofrio; Sharon Porrez; Bart Jacobs; Azhar Alhatemi; Fien De Boever; Gwenn Waerlop; Els Michels; Francesca Vanni; Alessandro Manenti; Geert Leroux-Roels et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

The Lancet Infectious Diseases
2024-07 | Journal article
DOI: 10.1016/s1473-3099(24)00375-x
Part of ISSN: 1473-3099
Contributors: Isabel Leroux-Roels; Chittappen Kandiyil Prajeeth; Amare Aregay; Niranjana Nair; Guus F Rimmelzwaan; Albert D M E Osterhaus; Simone Kardinahl; Sabrina Pelz; Stephan Bauer; Valentino D'Onofrio et al.
Source: Self-asserted source
Bart Jacobs

Safety and immunogenicity of a 4-component GMMA-based <i>Shigella</i> vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial

The Journal of Infectious Diseases
2024-06-10 | Journal article
DOI: 10.1093/infdis/jiae273
Part of ISSN: 0022-1899
Part of ISSN: 1537-6613
Contributors: Isabel Leroux-Roels; Cathy Maes; Francesca Mancini; Bart Jacobs; Eleanna Sarakinou; Azhar Alhatemi; Jasper Joye; Silvia Grappi; Giulia Luna Cilio; Alimamy Serry-Bangura et al.
Source: Self-asserted source
Bart Jacobs

Immune responses in healthy adults elicited by a bivalent norovirus vaccine candidate composed of GI.4 and GII.4 VLPs without adjuvant

FRONTIERS IN IMMUNOLOGY
2023 | Journal article
DOI: 10.3389/fimmu.2023.1188431
HANDLE: 1854/LU-01H7F8RK7E2M04APKF7V1DVJ6A
Contributors: Gwenn Waerlop; Yorick Janssens; Jacobs, Bart; Jarczowski, Franziska; Diessner, André; Geert Leroux-Roels; Klimyuk, Victor; Isabel Leroux-Roels; Thieme, Frank
Source: check_circle
Ghent University Academic Bibliography

Immunogenicity, safety, and preliminary efficacy evaluation of OVX836, a nucleoprotein-based universal influenza A vaccine candidate : a randomised, double-blind, placebo-controlled, phase 2a trial

LANCET INFECTIOUS DISEASES
2023 | Journal article
DOI: 10.1016/s1473-3099(23)00351-1
HANDLE: 1854/LU-01H6PBDZAVND3PKMRSN0EXNMBA
Contributors: Isabel Leroux-Roels; Willems, Paul; Gwenn Waerlop; Yorick Janssens; Tourneur, Jessika; De Boever, Fien; Bruhwyler, Jacques; Alhatemi, Azhar; Jacobs, Bart; Nicolas, Florence et al.
Source: check_circle
Ghent University Academic Bibliography

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine

FRONTIERS IN IMMUNOLOGY
2022 | Journal article
DOI: 10.3389/fimmu.2022.1021500
HANDLE: 1854/LU-8769973
Contributors: Isabel Leroux-Roels; Maes, Cathy; Joye, Jasper; Jacobs, Bart; Jarczowski, Franziska; Diessner, André; Yorick Janssens; Gwenn Waerlop; Tamminen, Kirsi; Heinimäki, Suvi et al.
Source: check_circle
Ghent University Academic Bibliography
How many people are using ORCID?